Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy company Passage Bio Inc.

OrbiMed Advisors led a $115.5 million series A round for Passage Bio, which debuted Thursday to develop gene therapies to treat rare monogenic CNS diseases. The newco’s co-founders include gene therapy pioneer James Wilson, Frazier Healthcare Partners’ Tachi Yamada and OrbiMed’s Stephen Squinto. Frazier, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures participated in the financing (see “Passage Bio Debuts with $115.5M for CNS Gene Therapies”)...